Published in Antimicrob Agents Chemother on October 01, 1989
In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob Agents Chemother (2006) 1.31
In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii. Antimicrob Agents Chemother (1994) 1.10
Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother (1994) 1.02
In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob Agents Chemother (1990) 0.98
Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures. Antimicrob Agents Chemother (1991) 0.94
In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii. Antimicrob Agents Chemother (1995) 0.90
A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans. PLoS One (2015) 0.89
Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice. Antimicrob Agents Chemother (1991) 0.82
Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity. Antimicrob Agents Chemother (2016) 0.75
Qinghaosu (artemisinin): an antimalarial drug from China. Science (1985) 4.95
Toxoplasmosis: the time has come. N Engl J Med (1988) 2.54
Specific labeling of intracellular Toxoplasma gondii with uracil. J Protozool (1977) 2.53
New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother (1984) 2.32
Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother (1988) 2.16
Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med (1987) 1.89
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother (1988) 1.61
Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice. Antimicrob Agents Chemother (1986) 1.59
A rapid micro method for the simultaneous determination of phagocytic-microbiocidal activity of human peripheral blood leukocytes in vitro. J Immunol Methods (1977) 1.57
Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy. Am J Trop Med Hyg (1987) 1.56
Acute toxoplasmosis. Effective treatment with pyrimethamine, sulfadiazine, leucovorin calcium, and yeast. JAMA (1960) 1.24
Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol (1997) 5.91
Swarming of Pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili. J Bacteriol (2000) 4.59
Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother (1989) 2.30
Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol (1999) 1.96
In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother (1986) 1.71
Activity of ten antimicrobial agents against anaerobic bacteria. J Antimicrob Chemother (1978) 1.66
Cellular events and intracellular survival of Campylobacter jejuni during infection of HEp-2 cells. Infect Immun (1989) 1.65
Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (1992) 1.62
Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother (1987) 1.62
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother (1988) 1.61
Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology (1990) 1.61
A plasmid-mediated cephalosporinase from Achromobacter species. J Infect Dis (1982) 1.55
Contribution of beta-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in Enterobacter cloacae. Antimicrob Agents Chemother (1987) 1.55
Treatment of vascular graft infection by in situ replacement with a rifampin-bonded gelatin-sealed Dacron graft. J Vasc Surg (1994) 1.51
Expression of host resistance to Salmonella typhi and Salmonella typhimurium: bacterial survival within macrophages of murine and human origin. Microb Pathog (1990) 1.42
Effect of motility and chemotaxis on the invasion of Salmonella typhimurium into HeLa cells. Microb Pathog (1990) 1.38
Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother (2003) 1.33
Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J Int Med Res (1996) 1.33
Identification of Campylobacter jejuni surface proteins that bind to Eucaryotic cells in vitro. Infect Immun (1990) 1.32
Combination therapy: a way to limit emergence of resistance? Am J Med (1986) 1.30
Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1991) 1.24
Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis (2001) 1.22
Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae. Antimicrob Agents Chemother (1991) 1.16
Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate. J Antimicrob Chemother (1990) 1.13
Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice. J Antimicrob Chemother (1988) 1.12
Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother (1991) 1.06
Effect of mucin on Campylobacter jejuni association and invasion on HEp-2 cells. Microb Pathog (1988) 1.05
Development of beta-lactam-resistant Enterobacter cloacae in mice. J Infect Dis (1987) 1.04
Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother (1994) 1.02
In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob Agents Chemother (1990) 0.98
C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob Agents Chemother (2001) 0.97
Activity of minocycline against Toxoplasma gondii infection in mice. J Antimicrob Chemother (1991) 0.96
Bacterial antibiotic efflux systems of medical importance. Cell Mol Life Sci (1999) 0.95
Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species. Antimicrob Agents Chemother (1989) 0.95
Fish oil decreases natural resistance of mice to infection with Salmonella typhimurium. Metabolism (1992) 0.95
Hydrolysis of Cefotaxime by a beta-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother (1980) 0.94
Genetic background of attenuated Salmonella typhimurium has profound influence on infection and cytokine patterns in human dendritic cells. J Leukoc Biol (2001) 0.94
[Serum, lymph node and testicular concentrations of penicillin in 31 healthy or syphilitic rabbits treated with penicillin]. Pathol Biol (Paris) (1971) 0.93
Respective role of polymorphonuclear leukocytes and their integrins (CD-11/18) in the local or systemic toxicity of lipopolysaccharide. J Leukoc Biol (1993) 0.93
Comparative study of the beta-lactamase activity found in Achromobacter. Can J Microbiol (1983) 0.91
Arteether, a qinghaosu derivative, in toxoplasmosis. Trans R Soc Trop Med Hyg (1988) 0.91
Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients. Antimicrob Agents Chemother (1976) 0.90
Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft. Ann Vasc Surg (1991) 0.90
Macrophage oxidative metabolism and intracellular Toxoplasma gondii. Microb Pathog (1989) 0.90
Evaluation of models for the mechanism of action of 4-hydroxyphenylpyruvate dioxygenase. Experientia (1981) 0.89
The chemotherapy of rodent malaria. L. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. Part 3: Observations on 'Fenozan-50F', a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane. Ann Trop Med Parasitol (1993) 0.89
Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J Antimicrob Chemother (1990) 0.89
Newly documented antimicrobial activity of quinolones. Eur J Clin Microbiol Infect Dis (1991) 0.89
A QSAR study of the antimalarial activity of some synthetic 1,2,4-trioxanes. J Chem Inf Comput Sci (1997) 0.88
Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother (1986) 0.87
The chemotherapy of rodent malaria. LX. The importance of formulation in evaluating the blood schizontocidal activity of some endoperoxide antimalarials. Ann Trop Med Parasitol (2002) 0.87
In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli. Infection (1994) 0.87
Usual and unusual antibacterial effects of quinolones. J Antimicrob Chemother (1990) 0.86
Second-generation antimalarial endoperoxides. Parasitol Today (1996) 0.86
Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora. A double-blind study. Drugs (1988) 0.85
Laboratory survey of fluoroquinolone activity. Rev Infect Dis (1989) 0.83
[Evolution of gentamicin sensitivity in acute postpartum staphylococcal endocarditis]. Ann Med Interne (Paris) (1972) 0.83
Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection. J Antimicrob Chemother (1988) 0.83
Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia. J Antimicrob Chemother (1987) 0.83
New bromoterpenes from the red alga Laurencia luzonensis. J Nat Prod (2001) 0.83
Postantibiotic effect and host-bacteria interactions. J Antimicrob Chemother (1995) 0.82
Overexpression, refolding, and purification of the histidine-tagged outer membrane efflux protein OprM of Pseudomonas aeruginosa. Protein Expr Purif (2001) 0.82
The chemotherapy of rodent malaria. XLVIII. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. Part 1: Studies leading to the development of novel cis-fused cyclopenteno derivatives. Ann Trop Med Parasitol (1993) 0.81
Treatment of vascular graft infection by in situ replacement with cryopreserved aortic allografts: an experimental study. J Vasc Surg (1998) 0.81
Salmonella typhimurium thyA mutants fail to grow intracellularly in vitro and are attenuated in mice. Microbiology (2001) 0.80
Anaerobic bacteria: evaluation of disc susceptibility to four cephalosporins. Infection (1978) 0.80
In-vitro toxoplasmacidal activity of cationic electron carriers. J Antimicrob Chemother (1989) 0.80
Open study of ceftazidime in serious infections due to multiply-resistant bacteria. J Antimicrob Chemother (1983) 0.79
Beta-lactamases: clinical and genetic perspectives. J Antimicrob Chemother (1983) 0.79
How predictable is development of resistance after beta-lactam therapy in Enterobacter cloacae infection? J Antimicrob Chemother (1989) 0.79
Activity of roxithromycin against Toxoplasma gondii in murine models. J Antimicrob Chemother (1987) 0.78
Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother (1994) 0.78
Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants. J Antimicrob Chemother (1992) 0.78
Experimental treatment of vascular graft infection due to Staphylococcus epidermidis by in situ replacement with a rifampin-bonded polyester graft. Ann Vasc Surg (2001) 0.78
Permeability and penicillin-binding protein alterations in Salmonella muenchen: stepwise resistance acquired during beta-lactam therapy. Antimicrob Agents Chemother (1989) 0.78
Serum levels of ciprofloxacin after single oral doses in patients with septicemia. Eur J Clin Microbiol Infect Dis (1989) 0.77
Dietary supplementation with fish oil enhances in vivo synthesis of tumor necrosis factor. Immunol Lett (1992) 0.77
[Encephalogram changes in common manifestations of herpetic primoinfection]. Ann Med Interne (Paris) (1969) 0.77
Highly active nitro-aromatic antiparasitic drugs. Pharmazie (1982) 0.76
Activity of amphotericin B and intraconazole against intraphagocytic Candida albicans. Eur J Clin Microbiol Infect Dis (1990) 0.76
Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology (1999) 0.76
Rifampicin loading of vascular grafts. J Antimicrob Chemother (1996) 0.75
Relative beta-lactamase- and transpeptidase-inhibitory activities of the new quinolone WIN-57273 in Staphylococcus aureus. Antimicrob Agents Chemother (1992) 0.75
Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Int J Antimicrob Agents (1999) 0.75
[Initial results of treament with rifampicin of some septicemic states, 4 of which with endocarditis]. Bull Mem Soc Med Hop Paris (1968) 0.75
Restrictive antibiotherapy after renal transplantation. Can Med Assoc J (1979) 0.75
[Morbidity, mortality and etiology of gas gangrene in Canada]. Union Med Can (1981) 0.75
[Synergism of trimethoprim-sulfamethoxazole association]. Pathol Biol (Paris) (1971) 0.75
[Indications for respiratory resuscitation technics in whooping cough]. Therapeutique (1968) 0.75
[Compounds of the beta-lactam group as inhibitors of beta-lactamases]. Rev Prat (1982) 0.75
[Streptococcal septicemia (excluding Osler's endocarditis)]. Rev Prat (1977) 0.75
[Scientific French in free-fall]. Union Med Can (1981) 0.75
[Therapeutic results of bactericidal antibiotic associations in septicemia]. Pathol Biol (Paris) (1971) 0.75
[Scarlatina]. Presse Med (1966) 0.75
[Is it possible to recognize aminoglycoside ototoxicity early using evoked potentials?]. Ann Med Interne (Paris) (1980) 0.75
Sch 29482: stability and inhibitory potency towards beta-lactamases from Gram-negative bacteria. J Antimicrob Chemother (1982) 0.75
[Determination of methoprime in organic liquids by a microbiological method]. Pathol Biol (Paris) (1970) 0.75
[Developement of serum and urine concentrations of rifampicin during treatment]. Pathol Biol (Paris) (1969) 0.75
Blood schizontocidal activity of selected 1,2,4-trioxanes (Fenozans) against the multidrug-resistant strain of Plasmodium yoelii nigeriensis (MDR) in vivo. Parasitology (2006) 0.75